Description
JAB-23E73 is a KRAS inhibitor specifically designed to target solid tumors harboring KRAS gene alterations, including colorectal cancer. This compound represents a new class of precision oncology agents that directly target mutated KRAS proteins, which are found in approximately 40-50% of colorectal cancers. JAB-23E73 is administered to patients with advanced solid tumors who have confirmed KRAS mutations through molecular testing. The drug is part of the emerging category of direct KRAS inhibitors that aim to block oncogenic KRAS signaling pathways.
Mechanism of Action
JAB-23E73 functions by directly binding to and inhibiting mutant KRAS proteins, preventing their interaction with downstream effector proteins in critical cellular signaling cascades. By blocking KRAS-mediated signaling pathways including RAF-MEK-ERK and PI3K-AKT, the drug disrupts cancer cell proliferation, survival signals, and tumor growth. This targeted approach specifically affects cells with KRAS mutations while sparing normal cells with wild-type KRAS.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.